Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback program, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Announcement - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board of directors has resolved to utilize the buyback authorization to repurchase shares in the open market at a total price of no less than HKD 100 million [1] - The proposed share buyback is seen as a demonstration of the company's confidence in its business development prospects [1] Group 2: Financial Position - The company believes that its existing financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]
锦欣生殖(01951)拟不少于1亿港元的总价格购回股份